We’re excited to share that our company, Quadrant Biosciences, has been awarded a $330,000 grant from the National Institutes of Health (NIH). This grant will support the next phase in our autism research.
Previously, the NIH awarded us a $2 million Phase II Small Business Technology Transfer (STTR) grant for the refinement and commercialization of an epigenetic autism diagnostic test focused on non-coding and microbial transcripts found in the saliva.
In this newest phase, Quadrant Biosciences will be examining the saliva of 1,000 children to learn more about the protein coding regions of the genome. These variations in the coding regions could help identify differences based on population ancestry. We’re hoping these results can enhance our ability to identify precise biomarkers that will improve the diagnosis, clinical care, and outcomes of individuals with ASD even more.
“We are very excited about the opportunity to explore the relationships between the protein-coding regions of the genome and the epigenetic biomarkers we’ve been studying for the past several years,” said Rich Uhlig, founder and CEO of Quadrant Biosciences.
To read more about the grant, click here.